Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Measuring MYD88/CXCR4 mutation allele fraction in Waldenström macroglobulinemia using a multiplex (7‐plex) ddPCR assay may have value both as a disease biomarker and as a prognostic indicator.”
Title: Prognostic value of MYD88/ CXCR4 mutation allele fraction in Waldenström macroglobulinemia using a multiplex ddPCR assay
Authors: Eleni Thanou, Ioannis Kollias, Eleni Kalafati, Christos Vlachos, Nefeli Mavrianou-Koutsoukou, Ourania Theologi, Maria Sakkou, Christine Liacos, Konstantina Taouxi, Alexandra Papadimou, Katerina Chrisostomidou, Agisilaos Papadopoulos, Maria Gavriatopoulou, Evangelos Terpos, Evi Lianidou, Meletios Dimopoulos, Efstathios Kastritis, Athina Markou, Tina Bagratuni
You can read the Full Article on HemaSphere.

You can find other articles featuring Robert Orlowski on OncoDaily.